EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Design, Synthesis, and Biological Evaluation of Chiral Urea and Thiourea Derivatives as Multitarget‐Directed Anti‐Alzheimer Agents

Sule Erol Gunal iD, Senel Teke Tuncel, İlke Demir, İpek Baysal, Gökçen Telli, Safiye Sag Erdem iD, Gulberk Ucar, Michaela Hanzlova, Kamil Musilek iD, İlknur Dogan, Nesrin Gokhan Kelekci iD

Drug Development Research · 2026

DOI: 10.1002/ddr.70341 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Drug Development Research, 2026. Verfasst von Sule Erol Gunal und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemistry, Bebek, Bogazici University, Istanbul, Turkey. Hauptthemen laut MEDLINE: Thiourea, Alzheimer Disease, Urea, Cholinesterase Inhibitors. Die Arbeit nennt 81 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Scientific and Technological Research Council of Turkey (TÜBİTAK), Bogazici University Research Fund (BAP), University of Hradec Kralove.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

A series of novel chiral urea and thiourea compounds were designed as multitarget‐directed ligands for Alzheimer's disease and evaluated against hAChE, hBChE, and hMAO‐B, with exploratory assessment of HSD10. These chiral compounds were synthesized and fully characterized, and their enantiopurity was confirmed via HPLC. Biological screening revealed that several of the 38 single‐enantiomer derivatives exhibited potent triple inhibition of hAChE, hBChE, and hMAO‐B. Biological screening revealed that a significant number of the 38 synthesized single‐enantiomer urea and thiourea derivatives potent inhibition across the primary target panel. Among them, compounds 14 S ( h AChE: 0.08 μM, h BChE: 0.93 μM, h MAO‐B: 0.02 μM), 23 R ( h AChE: 0.06 μM, h BChE: 0.74 μM, h MAO‐B: 0.08 μM), 6 S ( h AChE: 0.08 μM, h BChE: 0.65 μM, h MAO‐B: 0.08 μM), and 30 S ( h AChE: 0.04 μM, h BChE: 0.74 μM, h MAO‐B: 0.19 μM) showed the most promising multitarget profiles. Compounds 6 S and 23 R also displayed anti‐Aβ aggregation activity, whereas 12 S combined dual hMAO‐B/hAChE inhibition with antioxidant activity. Compounds 3 R and 11 R were found to be highly active against h MAO‐B (0.03 μM and 0.06 μM, respectively) and h BChE (0.68 and 0.72 μM). HSD10 inhibition was limited overall, with only compound 26 S showing moderate activity (52.2%) at higher micromolar concentration. Molecular docking and molecular dynamics simulations supported the proposed ligand‐target interactions for the most active compounds. In addition, selected derivatives showed no acute cytotoxicity under the tested conditions in HepG2 cells and high permeability potential in the PAMPA‐BBB assay. Based on their in vitro profiles, seven compounds ( 3 R , 6 S , 11 R , 12 S , 14 S , 23 R , and 30 S ) were advanced to in vivo evaluation, and compounds 6 S , 12 S , and 23 R , 30 S produced significant improvements in the Morris Water Maze model. Collectively, these findings identify chiral urea and thiourea derivatives as promising lead structures for further anti‐Alzheimer drug discovery.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ThioureaAlzheimer DiseaseUreaCholinesterase InhibitorsDrug DesignHumansStereoisomerismMolecular Docking SimulationStructure-Activity RelationshipMonoamine OxidaseAcetylcholinesteraseAnimalsAmyloid beta-Peptides

Substanzen

ThioureaUreaCholinesterase InhibitorsMonoamine OxidaseAcetylcholinesteraseAmyloid beta-Peptides

Autor:innen und Institutionen

  • Department of Chemistry, Bebek, Bogazici University, Istanbul, Turkey.
  • Department of Pharmaceutical Chemistry, Faculty of Pharmacy, İstanbul University-Cerrahpaşa, Istanbul, Turkey.
  • Department of Molecular Biology and Genetics, İstanbul Arel University, Istanbul, Turkey.
  • Department of Chemistry, Faculty of Science, Marmara University, Istanbul, Turkey.
  • Department of Pharmaceutical Sciences, Faculty of Pharmacy, Fenerbahçe University, Istanbul, Turkey.
  • Vocational School of Health Services, Hacettepe University, Ankara, Turkey.

ORCID-Profile: Sule Erol Gunal, Safiye Sag Erdem, Kamil Musilek, Nesrin Gokhan Kelekci

Förderung

  • Scientific and Technological Research Council of Turkey (TÜBİTAK)
  • Bogazici University Research Fund (BAP)
  • University of Hradec Kralove

Zitieren

APA

Erol Gunal, S., Teke Tuncel, S., Demir, İ., Baysal, İ., Telli, G., Sag Erdem, S., Ucar, G., Hanzlova, M., Musilek, K., Dogan, İ., & Gokhan Kelekci, N. (2026). Design, Synthesis, and Biological Evaluation of Chiral Urea and Thiourea Derivatives as Multitarget‐Directed Anti‐Alzheimer Agents. Drug Development Research. https://doi.org/10.1002/ddr.70341

Vancouver

Erol Gunal S, Teke Tuncel S, Demir İ, Baysal İ, Telli G, Sag Erdem S, et al. Design, Synthesis, and Biological Evaluation of Chiral Urea and Thiourea Derivatives as Multitarget‐Directed Anti‐Alzheimer Agents. Drug Development Research. 2026. doi:10.1002/ddr.70341

BibTeX
@article{ErolGunal2026,
  author = {Erol Gunal, Sule and Teke Tuncel, Senel and Demir, İlke and Baysal, İpek and Telli, Gökçen and Sag Erdem, Safiye and Ucar, Gulberk and Hanzlova, Michaela and Musilek, Kamil and Dogan, İlknur and Gokhan Kelekci, Nesrin},
  title = {Design, Synthesis, and Biological Evaluation of Chiral Urea and Thiourea Derivatives as Multitarget‐Directed Anti‐Alzheimer Agents},
  journal = {Drug Development Research},
  year = {2026},
  doi = {10.1002/ddr.70341}
}
Kostenlos starten →